CHANGES IN PHARMACOLOGICAL TREATMENT PATTERN FOR TYPE 2 DIABETES IN FIVE YEARS: BEFORE AND AFTER THE INTRODUCTION OF DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITOR AT A DIABETES SPECIALIST CLINIC IN TOKYO

被引：0
|
作者：
Watanabe, Y. [1 ]
Takayama, C. [2 ]
Asada, Y. [2 ]
Mori, T. [2 ]
Kawagoe, Y. [1 ]
Fujii, H. [1 ]
Miyakawa, T. [1 ]
机构：
[1] Tama Ctr Mirai Clin, Internal Med, Tokyo, Japan
[2] Yamato Prescript Ctr, Tokyo, Japan
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2014年 / 106卷
关键词：
D O I：
10.1016/S0168-8227(14)70492-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO198
引用
收藏
页码：S148 / S149
页数：2
相关论文
共 50 条
  • [41] Dipeptidyl peptidase-4 inhibitors in the treatment of type 2 diabetes: a comparative review
    Deacon, C. F.
    DIABETES OBESITY & METABOLISM, 2011, 13 (01): : 7 - 18
  • [42] Effect of a dipeptidyl peptidase 4 (DPP-4) inhibitor, vildagliptin, on gastrointestinal function, nutrient intake and glucose metabolism in type 2 diabetes
    Vella, A.
    Bock, G.
    Giesler, P. D.
    Burton, D. B.
    Foley, J. E.
    Rizza, R. A.
    Camilleri, M.
    NEUROGASTROENTEROLOGY AND MOTILITY, 2007, 19 (05): : 434 - 434
  • [43] Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
    Balijepalli, Chakrapani
    Shirali, Rohan
    Kandaswamy, Prashanth
    Ustyugova, Anastasia
    Pfarr, Egon
    Lund, Soren S.
    Druyts, Eric
    DIABETES THERAPY, 2018, 9 (04) : 1491 - 1500
  • [44] Cardiovascular Safety of Empagliflozin Versus Dipeptidyl Peptidase-4 (DPP-4) Inhibitors in Type 2 Diabetes: Systematic Literature Review and Indirect Comparisons
    Chakrapani Balijepalli
    Rohan Shirali
    Prashanth Kandaswamy
    Anastasia Ustyugova
    Egon Pfarr
    Søren S. Lund
    Eric Druyts
    Diabetes Therapy, 2018, 9 : 1491 - 1500
  • [45] DPP-4 inhibitor approved for the treatment of type 2 diabetes mellitus
    不详
    FORMULARY, 2009, 44 (09) : 261 - 261
  • [46] Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes
    Mega, Cristina
    Teixeira-Lemos, Edite
    Fernandes, Rosa
    Reis, Flavio
    JOURNAL OF DIABETES RESEARCH, 2017, 2017
  • [47] Use of the dipeptidyl peptidase-4 inhibitor linagliptin in combination therapy for type 2 diabetes
    Lajara, Rosemarie
    EXPERT OPINION ON PHARMACOTHERAPY, 2012, 13 (18) : 2663 - 2671
  • [48] Sitagliptin: A DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus
    Johnson, Kathryn M. S.
    Schurr, Kathleen
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2011, 3 : 81 - 92
  • [49] Alogliptin: A new dipeptidyl peptidase-4 inhibitor for the management of type 2 diabetes mellitus
    Ndefo, Uche Anadu
    Okoli, Okwuchukwu
    Erowele, Goldina
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2014, 71 (02) : 103 - 109
  • [50] Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes
    Hanefeld, Markolf
    Herman, Gary A.
    Wu, Mei
    Mickel, Carolyn
    Sanchez, Matilde
    Stein, Peter P.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (06) : 1329 - 1339
12345